Professor, Internal Medicine, Mayo Clinic College of Medicine Consultant, Division of Hematology Co-PI University of Iowa/Mayo Lymphoma SPORE Co-PI Hematology Malignancies Program in the Mayo Clinic Cancer Center
Hematology
Dr. Thomas E. Witzig, MD
|
|
Give Review
Doctor Thomas E. Witzig, MD is an expert in the field of Hematology. He went to University of Illinois College of Medicine. Doctor Thomas E. Witzig, MD is a published doctor as well. He has 102 publications published. The latest was: Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. He is registered with Medicare and accepts Medicare payments.
Publications
- Targeting the PD-1 pathway in patients with relapsed classic Hodgkin Lymphoma following allogeneic stem cell transplant is safe and effective.
- Large B-cell transformation in nodular lymphocyte predominant Hodgkin Lymphoma: forty-year experience from a single institution.
- Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
- Personalized risk prediction for event-free survival at 24 months in patients with diffuse large b-cell Lymphoma.
- A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin Lymphoma.
- Rituximab for IgG4-related Disease: a prospective, open-label trial.
- Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin Lymphoma.
- BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular Lymphoma.
- Elevated serum levels of IL-2R, IL-1RA and CXCL9 are associated with a poor prognosis in follicular Lymphoma.
- Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region.
- Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell Lymphoma.
- Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell Lymphoma.
- Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic Leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab ...
- Origins research in large cell Lymphoma-time for action?
- The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell Lymphoma and baseline bone marrow involvement.
- Recent advances in mantle cell Lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop.
- Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell Lymphoma.
- Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outc...
- Immunoglobulin G4-Related Disease of the Orbit: Imaging Features in 27 Patients.
- Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem Cell transplant.
- GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.
- Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell Lymphoma: implications for epigenetic therapy.
- Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin Lymphoma who received prior stem cell transplantation.
- A skin rash and what lies beneath: Paraneoplastic pemphigus, an atypical presentation of follicular cell Lymphoma.
- Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Researc...
- CXCR5 polymorphisms in non-Hodgkin Lymphoma risk and prognosis.
- Outcomes of patients with POEMS Syndrome treated initially with radiation.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- A phase i trial of immunostimulatory CpG 7909 oligodeoxynucleotide and (90) yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-hodgkin Lymphoma.
- Recurrent Acute inflammatory demyelinating polyradiculoneuropathy following R-CHOP treatment for non-Hodgkin lymphoma.
- High levels of peripheral blood circulating plasma Cells as a specific risk factor for progression of smoldering multiple myeloma.
- Recent advances in mantle cell Lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.
- Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase.
- Systemic amyloidosis associated with chronic lymphocytic Leukemia/small lymphocytic lymphoma.
- Moving radioimmunotherapy forward for follicular Lymphoma.
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple Myeloma.
- Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases.
- Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience.
- Lack of JAK2 activating non-synonymous mutations in diffuse large B-Cell tumors: JAK2 deregulation still unexplained.
- Trends and outcomes of modern staging of solitary plasmacytoma of bone.
- Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell Lymphoma.
- Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell Lymphoma patients.
- Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin Lymphoma.
- Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin Lymphoma and synergizes with the mTOR inhibitor rapamycin.
- The Absolute Monocyte Count is Associated with Overall Survival in Patients Newly Diagnosed with Follicular Lymphoma.
- Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
- Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom's Macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.
- Species D Adenoviruses as Oncolytics Against B Cell Cancers.
- The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS Syndrome.
- Hematologist/oncologist disease-specific expertise and survival: Lessons from chronic lymphocytic Leukemia (CLL)/small lymphocytic lymphoma (SLL).
- A Phase I Clinical Trial of CpG Oligonucleotide 7909 (PF-03512676) in Patients with Previously Treated Chronic Lymphocytic Leukemia.
- Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic Leukemia.
- Bone marrow stromal cells protect Lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory Lymphomas.
- Soluble IL-2R{alpha} facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin Lymphoma.
- The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin Lymphoma of distinct histological origin.
- Cytotoxicity of farnesyltransferase inhibitors in lymphoid Cells mediated by MAPK pathway inhibition and Bim upregulation.
- Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cel...
- Treatment recommendations for radioimmunotherapy in follicular Lymphoma: a consensus conference report.
- Establishment and characterization of a novel Waldenstrom Macroglobulinemia cell line, MWCL-1.
- Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell Lymphoma.
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple Myeloma: Results from a phase 2 trial.
- Higher response to lenalidomide in relapsed/refractory diffuse large b-cell Lymphoma in nongerminal center b-cell-like than in germinal center b-cell-like phenotype.
- Orbital Inflammation With IgG4-Positive Plasma Cells: Manifestation of IgG4 Systemic Disease.
- GLI2 mediates cytokine crosstalk in the tumor microenvironment.
- Vitamin D insufficiency and prognosis in chronic lymphocytic Leukemia.
- Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin Lymphoma.
- Design and validity of a clinic-based case-control study on the molecular epidemiology of Lymphoma.
- A BAFF-R mutation associated with non-Hodgkin Lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling.
- Germline variation in apoptosis pathway genes and risk of non-Hodgkin's Lymphoma.
- Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) Myeloma.
- Vitamin D insufficiency and prognosis in non-Hodgkin's Lymphoma.
- Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed Myeloma.
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- Reply to J.R. Carver et al.
- Evidence for cytogenetic and fluorescence in Situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
- The treatment of recurrent/refractory chronic lymphocytic Leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of C...
- A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin Lymphoma.
- Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom Macroglobulinemia.
- Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple Myeloma: a comparative analysis of 411 patients.
- Statin use and prognosis in patients with diffuse large B-cell Lymphoma and follicular Lymphoma in the rituximab era.
- Signal transduction inhibitor therapy for Lymphoma.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
- Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell Lymphoma by inhibiting Akt signaling through mTORC2.
- Monocytes promote tumor cell survival in T-cell lymphoproliferative Disorders and are impaired in their ability to differentiate into mature dendritic cells.
- B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative Disorders.
- Impact of risk stratification on outcome among patients with multiple Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's Lymphoma.
- MicroRNAs 15a and 16 regulate tumor proliferation in multiple Myeloma.
- A proliferation-inducing ligand mediates follicular Lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian ta...
- Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin Lymphoma.
- Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic Leukemia.
- Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell Lymphoma.
- Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin Lymphoma.
- Induction of a chronic Disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the...
- A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular Lymphoma.
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
- Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central C...
- Targeting NF-kappaB in Waldenstrom Macroglobulinemia.
- Genetically predicted longer telomere length is associated with increased risk of B-cell Lymphoma subtypes.
Schools
University Of Illinois College Of Medicine Chicago
University Ia Hospital
Mayo Clinic Rochester
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Mayo School of Graduate Medical Education -
University of Iowa Hospitals and Clinics -
University of Illinois College of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1508846791 | |
| NPPES Provider LastName | WITZIG | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 217.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508846791 |
| Last Name Of The Provider | WITZIG |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
|
Dr. Mark R. Litzow, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. C Christopher Hook, MD |
|
|
Dr. Kiernan J. Minehan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rafael Santana-Davila, MD |
|
|
Dr. Rattiya Cheewakriangkrai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joleen M. Hubbard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James D. Hoyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yi Lin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William L. Nichols, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott H. Kaufmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Phyliky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela Dispenzieri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan E. Wilcox, MD |
|
|
Dr. Robert R. McWilliams, MD |
|
|
Dr. Brian J. Davis, MD |
|
|
Dr. Mary M. Gallenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stefan F. Cordes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Preet P. Singh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evidio Domingo Musibay, MD
This Doctor is OpenDoctor Recommended.
|